Clinical Trial to Evaluate the Efficacy of Probit-Based Triple Therapy for Helicobacter Pylori Eradication

1. Male or female, aged 19 to 75 years at consent.
2. Confirmed H. pylori positive by urease breath or enzyme test.
3. Require eradication therapy due to at least one condition: chronic atrophic gastritis, peptic ulcer, history of early gastric cancer or adenoma resection, functional dyspepsia, low-grade MALT lymphoma, idiopathic thrombocytopenic purpura, iron deficiency anemia, hyperplastic polyps, or family history of gastric cancer.
4. Agree to use medically acceptable contraception during the trial (including medically sterile women such as menopausal, hysterectomy, tubal ligation, or bilateral oophorectomy).
5. Provide voluntary written informed consent.

Exclusion Criteria:

1. History of receiving H. pylori eradication therapy prior to study participation.
2. Known hypersensitivity to the investigational product, penicillin-class antibiotics, or macrolide-class antibiotics.
3. Current use of medications contraindicated with the investigational product or concomitant therapy.
4. Abnormal laboratory values in blood chemistry tests as defined by the protocol.
5. pregnant or nursing women